Cronos Group (CRON) Competitors $2.52 -0.10 (-3.82%) Closing price 04:00 PM EasternExtended Trading$2.50 -0.02 (-0.60%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRON vs. ACB, CGC, OGI, SNDL, TLRY, KRYS, CYTK, ADMA, PCVX, and ZLABShould you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Aurora Cannabis (ACB), Canopy Growth (CGC), Organigram Global (OGI), SNDL (SNDL), Tilray Brands (TLRY), Krystal Biotech (KRYS), Cytokinetics (CYTK), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Cronos Group vs. Its Competitors Aurora Cannabis Canopy Growth Organigram Global SNDL Tilray Brands Krystal Biotech Cytokinetics ADMA Biologics Vaxcyte Zai Lab Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation. Do insiders & institutionals believe in CRON or ACB? 8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 7.3% of Cronos Group shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is CRON or ACB more profitable? Cronos Group has a net margin of 14.19% compared to Aurora Cannabis' net margin of -5.66%. Aurora Cannabis' return on equity of -1.49% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group14.19% -3.78% -3.62% Aurora Cannabis -5.66%-1.49%-1.06% Which has more volatility and risk, CRON or ACB? Cronos Group has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Does the media prefer CRON or ACB? In the previous week, Aurora Cannabis had 3 more articles in the media than Cronos Group. MarketBeat recorded 18 mentions for Aurora Cannabis and 15 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.57 beat Aurora Cannabis' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend CRON or ACB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Which has higher valuation & earnings, CRON or ACB? Cronos Group has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.61M8.22$41.08M$0.0550.40Aurora Cannabis$246.72M1.23$1.63M-$0.19-28.37 SummaryAurora Cannabis beats Cronos Group on 9 of the 16 factors compared between the two stocks. Get Cronos Group News Delivered to You Automatically Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRON vs. The Competition Export to ExcelMetricCronos GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$2.48B$5.62B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio50.4022.0530.2925.74Price / Sales8.22735.09462.79115.73Price / Cash5,630.53184.4138.2159.48Price / Book0.864.838.826.15Net Income$41.08M$31.61M$3.25B$265.06M7 Day Performance11.01%3.93%4.05%2.80%1 Month Performance21.74%3.32%4.32%1.68%1 Year Performance7.23%13.53%36.25%29.59% Cronos Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRONCronos Group0.8678 of 5 stars$2.52-3.8%N/A+12.4%$1.01B$117.61M50.40450Earnings ReportAnalyst RevisionGap DownACBAurora Cannabis0.671 of 5 stars$5.21+16.3%N/A-17.3%$294.10M$246.72M-27.421,130Analyst RevisionGap DownHigh Trading VolumeCGCCanopy Growth0.6931 of 5 stars$1.58+26.4%N/A-75.9%$324.14M$225.65M-0.523,150Positive NewsEarnings ReportOptions VolumeAnalyst RevisionGap DownHigh Trading VolumeOGIOrganigram Global1.3244 of 5 stars$1.64+13.5%N/A-11.6%$219.81M$117.47M16.40860News CoverageEarnings ReportGap DownHigh Trading VolumeSNDLSNDL2.2224 of 5 stars$2.01+19.3%$4.00+99.5%+0.5%$526.87M$944.25M-7.432,516News CoverageOptions VolumeGap DownHigh Trading VolumeTLRYTilray Brands2.3881 of 5 stars$0.92+41.7%$1.92+108.6%-33.0%$1.01B$821.31M-0.402,842Options VolumeGap DownHigh Trading VolumeKRYSKrystal Biotech4.5472 of 5 stars$137.54-0.8%$210.22+52.8%-20.3%$3.98B$290.52M27.96210CYTKCytokinetics3.6836 of 5 stars$33.23-2.6%$70.69+112.7%-34.2%$3.98B$18.47M-6.52250Earnings ReportADMAADMA Biologics4.2874 of 5 stars$16.40-0.7%$27.67+68.7%-0.4%$3.91B$426.45M19.07530PCVXVaxcyte2.1176 of 5 stars$29.67-0.8%$136.50+360.1%-59.1%$3.85BN/A-7.22160Analyst RevisionZLABZai Lab2.4091 of 5 stars$34.66-0.9%$57.22+65.1%+119.3%$3.85B$398.99M-16.991,869News CoverageEarnings ReportAnalyst ForecastInsider Trade Related Companies and Tools Related Companies ACB Alternatives CGC Alternatives OGI Alternatives SNDL Alternatives TLRY Alternatives KRYS Alternatives CYTK Alternatives ADMA Alternatives PCVX Alternatives ZLAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRON) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cronos Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access